Research progress on osteoclasts activated by receptor activator of nuclear factor-κB ligand signaling pathway for the treatment of bone tuberculosis

doi:10.19982/j.issn.1000-6621.20240103

Abstract

Abstract:

Bone tuberculosis represents a grave orthopedic infectious disease that poses significant threats to human health. The hallmark of the disease is the absorption and subsequent destruction of bone tissue, primarily mediated by osteoclasts. These multinucleated cells, originating from hematopoietic stem cells, are primarily regulated by the receptor activator of nuclear factor-κB ligand (RANKL) and its receptor, RANK. Mycobacterium tuberculosis triggers osteoclasts to produce transcription factors via the RANKL signaling pathway, thus intensifying the degradation of bone. This review delineates the architecture of the RANKL signaling pathway, explores recent advances in osteoclast research, and discusses their prospective applications in the clinical management of bone tuberculosis, offering novel insights for future investigations.

Key words: Tuberculosis, osteoarticular, Receptor activator of nuclear factor-kappa B, Signal transduction, Osteoclasts, Summary report

CLC Number:

R529.2

Tian Hongjing, Zhang Yanjun, Deng Qiang, Li Junjie, Yang Jun, Liu Xinfeng, Du Jianqiang. Research progress on osteoclasts activated by receptor activator of nuclear factor-κB ligand signaling pathway for the treatment of bone tuberculosis[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 971-975. doi: 10.19982/j.issn.1000-6621.20240103

References 41

[1]	Steyn M, Scholtz Y, Botha D, et al. The changing face of tuberculosis: trends in tuberculosis-associated skeletal changes. Tuberculosis (Edinb), 2013, 93(4): 467-474. doi:10.1016/j.tube.2013.04.003.
[2]	Ono T, Nakashima T. Recent advances in osteoclast biology. Histochem Cell Biol, 2018, 149(4): 325-341. doi:10.1007/s00418-018-1636-2. pmid: 29392395
[3]	Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab, 2021, 39(1): 19-26. doi:10.1007/s00774-020-01162-6. pmid: 33079279
[4]	赵鸿健, 郭谦, 董子健, 等. 破骨前体细胞异质性与破骨细胞分化之间的联系. 骨科, 2023, 14(2): 187-191. doi:10.3969/j.issn.1674-8573.2023.02.017.
[5]	Nelson CA, Warren JT, Wang MW, et al. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure, 2012, 20(11): 1971-1982. doi:10.1016/j.str.2012.08.030. pmid: 23039992
[6]	Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997, 390(6656): 175-179. doi:10.1038/36593.
[7]	Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov, 2013, 12(2): 147-168. doi:10.1038/nrd3930. pmid: 23334208
[8]	Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397(6717): 315-323. doi:10.1038/16852.
[9]	Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A, 2000, 97(4): 1566-1571. doi:10.1073/pnas.97.4.1566.
[10]	Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997, 390(6656): 175-179. doi:10.1038/36593.
[11]	Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab, 2012, 23(11): 582-590. doi:10.1016/j.tem.2012.05.005.
[12]	Kapur RP, Yao Z, Iida MH, et al. Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. J Bone Miner Res, 2004, 19(10): 1689-1697. doi:10.1359/JBMR.040713. pmid: 15355564
[13]	Akatsu T, Takahashi N, Udagawa N, et al. Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J Bone Miner Res, 1991, 6(2): 183-189. doi:10.1002/jbmr.5650060212. pmid: 2028836
[14]	Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys, 2008, 473(2): 139-146. doi:10.1016/j.abb.2008.03.018. pmid: 18395508
[15]	Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem, 1997, 272(40): 25190-25194. doi:10.1074/jbc.272.40.25190. pmid: 9312132
[16]	Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997, 390(6656): 175-179. doi:10.1038/36593.
[17]	Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 1999, 402(6759): 304-309. doi:10.1038/46303.
[18]	Bord S, Ireland DC, Beavan SR, et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone, 2003, 32(2): 136-141. doi:10.1016/s8756-3282(02)00953-5. pmid: 12633785
[19]	Robling AG, Bonewald LF. The Osteocyte: New Insights. Annu Rev Physiol, 2020, 82: 485-506. doi:10.1146/annurev-physiol-021119-034332. pmid: 32040934
[20]	Madel MB, Ibáñez L, Wakkach A, et al. Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions. Front Immunol, 2019, 10: 1408. doi:10.3389/fimmu.2019.01408.
[21]	Mansour A, Wakkach A, Blin-Wakkach C. Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma. Front Immunol, 2017, 8: 954. doi:10.3389/fimmu.2017.00954. pmid: 28848556
[22]	Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol, 2019, 19(10): 626-642. doi:10.1038/s41577-019-0178-8. pmid: 31186549
[23]	Hikosaka Y, Nitta T, Ohigashi I, et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity, 2008, 29(3): 438-450. doi:10.1016/j.immuni.2008.06.018. pmid: 18799150
[24]	Mizuno A, Kanno T, Hoshi M, et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab, 2002, 20(6): 337-344. doi:10.1007/s007740200049. pmid: 12434161
[25]	Shin B, Yu J, Park ES, et al. Secretion of a truncated osteopetrosis-associated transmembrane protein 1 (OSTM1) mutant inhibits osteoclastogenesis through down-regulation of the B lymphocyte-induced maturation protein 1 (BLIMP1)-nuclear factor of activated T cells c1 (NFATc1) axis. J Biol Chem, 2014, 289(52): 35868-35881. doi:10.1074/jbc.M114.589614. pmid: 25359771
[26]	Deng J, Yang Y, He J, et al. Vitamin D receptor activated by vitamin D administration alleviates Mycobacterium tuberculosis-induced bone destruction by inhibiting NFκB-mediated aberrant osteoclastogenesis. FASEB J, 2021, 35(6): e21543. doi:10.1096/fj.202100135R.
[27]	Wei CM, Liu Q, Song FM, et al. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo. J Cell Physiol, 2018, 233(1): 476-485. doi:10.1002/jcp.25907.
[28]	Thummuri D, Jeengar MK, Shrivastava S, et al. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling. Pharmacol Res, 2015, 99: 63-73. doi:10.1016/j.phrs.2015.05.006. pmid: 26022736
[29]	Thummuri D, Naidu VGM, Chaudhari P. Carnosic acid attenua-tes RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling. J Mol Med (Berl), 2017, 95(10): 1065-1076. doi:10.1007/s00109-017-1553-1. pmid: 28674855
[30]	Chen X, Wang Z, Duan N, et al. Osteoblast-osteoclast intera-ctions. Connect Tissue Res, 2018, 59(2): 99-107. doi:10.1080/03008207.2017.1290085.
[31]	梁思敏, 蔡则成, 王志强, 等. 结核杆菌裂解物刺激后的成骨细胞来源外泌体对破骨细胞的影响. 中国脊柱脊髓杂志, 2021, 31(1): 69-75. doi:10.3969/j.issn.1004-406X.2021.01.10.
[32]	Wright KM, Friedland JS. Differential regulation of chemokine secretion in tuberculous and staphylococcal osteomyelitis. J Bone Miner Res, 2002, 17(9): 1680-1690. doi:10.1359/jbmr.2002.17.9.1680. pmid: 12211439
[33]	Zhang Y, Liu X, Li K, et al. Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts. Exp Ther Med, 2015, 9(3): 919-924. doi:10.3892/etm.2014.2153.
[34]	Bergh JJ, Xu Y, Farach-Carson MC. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. Endocrinology, 2004, 145(1): 426-436. doi:10.1210/en.2003-0319. pmid: 14525906
[35]	徐亦文, 曹阳, 安蒂, 等. 自噬在破骨细胞分化过程中的调控作用. 现代免疫学, 2016, 36(5): 400-404.
[36]	Vaishnav B, Suthar N, Shaikh S, et al. Clinical study of spinal tuberculosis presenting with neuro-deficits in Western India. Indian J Tuberc, 2019, 66(1): 81-86. doi:10.1016/j.ijtb.2018.04.009. pmid: 30797289
[37]	王增顺, 索南昂秀, 刘立民, 等. 自噬在结核菌素诱导破骨细胞形成中的作用及机制. 脊柱外科杂志, 2022, 20(1): 45-51. doi:10.3969/j.issn.1672-2957.2022.01.009.
[38]	Arai A, Kim S, Goldshteyn V, et al. Beclin1 Modulates Bone Homeostasis by Regulating Osteoclast and Chondrocyte Differen-tiation. J Bone Miner Res, 2019, 34(9): 1753-1766. doi:10.1002/jbmr.3756.
[39]	Mootoo A, Stylianou E, Arias MA, et al. TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets, 2009, 8(1): 53-62. doi:10.2174/187152809787582543. pmid: 19275693
[40]	马赫, 张建群, 梁思敏, 等. 肿瘤坏死因子-α与破骨细胞形成的关系初探. 宁夏医科大学学报, 2018, 40(1): 17-20, 41. doi:10.16050/j.cnki.issn1674-6309.2018.01.004.
[41]	夏琳. TNF-α对RANKL体外诱导破骨细胞分化的促进作用及其机制探讨. 济南: 山东大学, 2013.